Kirkham et al., 2022 [285] showed a statistically significant increase in GDF-15 levels at post-cycle 4 of trastuzumab compared to baseline in HER2-positive breast cancer patients (p ≤ 0.001). This evidence concerns the gene ERBB2 and breast carcinoma.